Researchers detected antibodies against SARS-CoV-2 using two different serology tests in nine participants’ samples.
The positive samples came as early as Jan.
Researchers in this study followed CDC guidance to use sequential testing on two separate platforms to minimize false positive results.
All of Us worked with Quest Diagnostics to test samples on the Abbott Architect SARS-CoV-2 IgG ELISA and the EUROIMMUN SARS-CoV-2 ELISA (IgG) platforms.“Antibody testing of blood samples helps us better understand the spread of SARS-CoV-2 in the U.S.In the All of Us study, researchers looked in participant samples for a type of antibodies called IgG.
In this study, the first positive samples came from participants in Illinois and Massachusetts on Jan.
While the study included samples from across the U.S., the number of samples from many states was low
In addition, the authors do not know whether the participants with positive samples became infected during travel or while in their own communities
All of Us expects to release more information following further analysis, and will offer participants whose samples were included in the study an opportunity to receive their individual resultsAbout the All of Us Research Program: The mission of the All of Us Research Program is to accelerate health research and medical breakthroughs, enabling individualized prevention, treatment, and care for all of usThe program will partner with one million or more people across the United States to build the most diverse biomedical data resource of its kind, to help researchers gain better insights into the biological, environmental, and behavioral factors that influence health
Althoff KN, et al, “Antibodies to SARS-CoV-2 in All of Us Research Program Participants,†January 2-March 18, 2020, Clinical Infectious Diseases, 2021; https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciab519